Plain-English translation of NCT04521803 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing whether a higher dose of rifampicin — a core tuberculosis medication — helps more effectively treat a serious condition called tuberculous pericarditis, which occurs when tuberculosis infects the lining around the heart and causes fluid to build up. Half of the participants will receive standard doses of this medication as usual, while the other half will receive a higher dose for the first two months. Researchers want to understand if the higher dose leads to better outcomes for this life-threatening infection.
Tuberculosis of the heart lining is a severe, often life-threatening form of TB that can be hard to treat with standard medication doses. This trial exists to see whether giving patients a higher dose of the medication early on can improve their chances of recovery and reduce complications.
You likely qualify if…
You likely don't qualify if…
If you join this trial, you will be randomly assigned to take either standard-dose tuberculosis medication or a higher dose of the medication for the first two months, followed by four months of standard-dose medication for both groups. You will need to undergo a heart procedure to drain fluid around your heart (if clinically needed), and you may be asked to have heart imaging scans and blood tests at various visits to monitor your progress. The trial involves visits at one of two research sites in South Africa over approximately six months.
AI-generated summary from trial data · Jun 3, 2026 · Not medical advice
South Africa